Drug intelligence / Profile preview

rosa canina vitamin c fraction

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

Rosa canina vitamin C fraction is a specific biochemical extract obtained from the hips of the dog rose (*Rosa canina*). In experimental models using human colon cancer cell lines (Caco-2), this fraction has demonstrated significant cytotoxicity and antiproliferative activity. Its mechanism involves the reduction of reactive oxygen species (ROS) and the induction of cell cycle disturbances, ultimately leading to programmed cell death via the apoptotic pathway. Due to these properties, it is being explored as a potential therapeutic agent or a functional food ingredient for the management of colorectal carcinoma.

Other names: Rosa canina hips fraction 2rosehip vitamin C fraction

Beyond the preview

Go deeper on rosa canina vitamin c fraction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rosa canina vitamin c fraction.

Explore the full profile